You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CYTOSAR-U Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cytosar-u, and what generic alternatives are available?

Cytosar-u is a drug marketed by Teva Pharms Usa and is included in one NDA.

The generic ingredient in CYTOSAR-U is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cytosar-u

A generic version of CYTOSAR-U was approved as cytarabine by HIKMA on August 2nd, 1989.

  Try a Trial

Drug patent expirations by year for CYTOSAR-U
Recent Clinical Trials for CYTOSAR-U

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Therapeutic Advances in Childhood Leukemia ConsortiumPhase 1/Phase 2
ADC TherapeuticsPhase 1
Academic and Community Cancer Research UnitedPhase 2

See all CYTOSAR-U clinical trials

US Patents and Regulatory Information for CYTOSAR-U

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa CYTOSAR-U cytarabine INJECTABLE;INJECTION 075206-004 Dec 30, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Usa CYTOSAR-U cytarabine INJECTABLE;INJECTION 075206-002 Dec 30, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Usa CYTOSAR-U cytarabine INJECTABLE;INJECTION 075206-003 Dec 30, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Usa CYTOSAR-U cytarabine INJECTABLE;INJECTION 075206-001 Dec 30, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CYTOSAR-U

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pacira Limited DepoCyte cytarabine EMEA/H/C/000317
Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.
Withdrawn no no no 2001-07-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.